EyeGate Raises $2 Million

EyeGate Pharma, a Paris-based developer of iontophoresis technology to non-invasively deliver therapeutics for ocular indications, has raised $2 million in additional Series B funding from The Nexus Group. The round total now stands at $12 million, with first-tranche backers including Innoven Partenaires and Ventech. www.eyegatepharma.com